Physician profile
James Troken
NPI 1538515101
$895.20
in general payments reported to CMS, 2019-2025
10 companies · $93.07 in 2025
The $93.07 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $108 · 2022: $107 · 2023: $266 · 2024: $62.56 · 2025: $93.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $358 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.85 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $178.21 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.47 | 2019-2020 | |
| Scpharmaceuticals INC. | $136.96 | 2023 | |
| Medtronic, INC. | $133.84 | 2022-2025 | Endurant Iis |
| Novo Nordisk INC | $99.48 | 2023-2025 | Ozempic, Wegovy |
| Actelion Pharmaceuticals US, INC. | $63.99 | 2023 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $41.45 | 2025 | Shingrix, Arexvy |
| Boston Scientific Corporation | $37.25 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $20.08 | 2019 | |
| Dexcom, INC. | $17.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Troken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.